1. Market Research
  2. > All Companies
  3. > Generex Biotechnology Corporation (GNBT) - Financial and Strategic SWOT Analysis Review

Generex Biotechnology Corporation (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Generex Biotechnology Corporation (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. The company focuses on drug delivery system of large molecules in the areas of seasonal influenza virus, melanoma, ovarian cancer, HIV, HPV, allergy and Type I diabetes mellitus. It has a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company through its subsidiary, Antigen, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations. The proprietary and proven advanced technology platform consists of buccal delivery technology and immunomedicines for the administration of formulations of large molecule drugs to the oral cavity. It has licensing and distribution agreements with various companies to sell its products worldwide. The company has presence in various countries including the US, Canada, South Africa, Republic of Latvia and Bermuda. Generex is headquartered in Burlington, Ontario, Canada.

Generex Biotechnology Corporation Key Recent Developments

Jun 05, 2015: Generex Biotechnology Reports Q3 Fiscal 2015 Results
Apr 07, 2015: Generex Acknowledges the Contributions of Its Chairman
Mar 12, 2015: Generex Provides Update on Buccal Insulin Formulation Enhancement Project
Mar 06, 2015: Generex Biotechnology Reports Q2 Fiscal 2015 Results
Aug 13, 2013: Generex Announces Podium Presentation on Antigen Express Cancer Vaccine Strategy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Generex Biotechnology Corporation (GNBT) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Generex Biotechnology Corporation - Key Facts 6
Generex Biotechnology Corporation - Key Employees 7
Generex Biotechnology Corporation - Key Employee Biographies 8
Generex Biotechnology Corporation - Major Products and Services 9
Generex Biotechnology Corporation - Pharmaceutical Pipeline Products Data 10
Generex Biotechnology Corporation, Pipeline Products by Therapy Area 10
Generex Biotechnology Corporation, Pipeline Products by Development Phase 11
Generex Biotechnology Corporation - History 12
Generex Biotechnology Corporation - Company Statement 16
Generex Biotechnology Corporation - Locations And Subsidiaries 19
Head Office 19
Other Locations and Subsidiaries 19
Section 2 - Company Analysis 20
Generex Biotechnology Corporation - Business Description 20
Generex Biotechnology Corporation - Corporate Strategy 21
Generex Biotechnology Corporation - SWOT Analysis 22
SWOT Analysis - Overview 22
Generex Biotechnology Corporation - Strengths 22
Strength - Proprietary Technologies 22
Strength - Strategic Partnerships 22
Strength - Robust Intellectual Property Portfolio 22
Generex Biotechnology Corporation - Weaknesses 23
Weakness - Legal Proceedings 23
Weakness - Lack of Product Revenue 23
Generex Biotechnology Corporation - Opportunities 24
Opportunity - Pipeline Products 24
Opportunity - Market Potential: Diabetes 24
Opportunity - Inorganic Growth Strategies 24
Generex Biotechnology Corporation - Threats 25
Threat - Uncertain RandD Outcomes 25
Threat - Stringent Government Regulations 25
Threat - Intense Competition 25
Generex Biotechnology Corporation - Key Competitors 26
Section 3 - Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 28
Performance Chart 29
Financial Performance 29
Financial Ratios - Interim Ratios 30
Financial Ratios - Ratio Charts 31
Section 4 - Company's Lifesciences Financial Deals and Alliances 32
Generex Biotechnology Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 32
Generex Biotechnology Corporation, Medical Equipment, Deals By Type, 2009 to YTD 2015 33
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 34
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 35
Generex Biotechnology Corporation, Recent Deals Summary 36
Section 5 - Company's Recent Developments 37
Jun 05, 2015: Generex Biotechnology Reports Q3 Fiscal 2015 Results 37
Apr 07, 2015: Generex Acknowledges the Contributions of Its Chairman 38
Mar 12, 2015: Generex Provides Update on Buccal Insulin Formulation Enhancement Project 39
Mar 06, 2015: Generex Biotechnology Reports Q2 Fiscal 2015 Results 40
Dec 12, 2014: Generex Biotechnology Reports Q1 Fiscal 2015 Results 41
Oct 03, 2014: Generex Biotechnology Reports Fiscal 2014 Results 42
Jun 06, 2014: Generex Biotechnology Reports Q3 Fiscal 2014 Results 44
Mar 07, 2014: Generex Biotechnology Reports Q2 Fiscal 2014 Results 45
Section 6 - Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Generex Biotechnology Corporation, Key Facts 6
Generex Biotechnology Corporation, Key Employees 7
Generex Biotechnology Corporation, Key Employee Biographies 8
Generex Biotechnology Corporation, Major Products and Services 9
Generex Biotechnology Corporation, Number of Pipeline Products by Therapy Area 10
Generex Biotechnology Corporation, Number of Pipeline Products by Development Stage 11
Generex Biotechnology Corporation, Pipeline Products By Therapy Area and Development Phase 11
Generex Biotechnology Corporation, History 12
Generex Biotechnology Corporation, Subsidiaries 19
Generex Biotechnology Corporation, Key Competitors 26
Generex Biotechnology Corporation, Ratios based on current share price 27
Generex Biotechnology Corporation, Annual Ratios 28
Generex Biotechnology Corporation, Interim Ratios 30
Generex Biotechnology Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 32
Generex Biotechnology Corporation, Medical Equipment, Deals By Type, 2009 to YTD 2015 33
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 34
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 35
Generex Biotechnology Corporation, Recent Deals Summary 36
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49

List of Figures
Generex Biotechnology Corporation, Pipeline Products by Therapy Area 10
Generex Biotechnology Corporation, Pipeline Products by Development Phase 11
Generex Biotechnology Corporation, Performance Chart (2011 - 2015) 29
Generex Biotechnology Corporation, Ratio Charts 31
Generex Biotechnology Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 32
Generex Biotechnology Corporation, Medical Equipment, Deals by Type, 2009 to YTD 2015 33
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 34
Generex Biotechnology Corporation, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
H1N1 Infection - Pipeline Review, H1 2016

H1N1 Infection - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • April 2016
  • by Global Markets Direct

H1N1 Infection - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H1 2016’, provides an overview of the H1N1 Infection pipeline landscape. The report provides ...

H3N2 Infection - Pipeline Review, H1 2016

H3N2 Infection - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • March 2016
  • by Global Markets Direct

H3N2 Infection - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2016’, provides an overview of the H3N2 Infection pipeline landscape. The report provides ...

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016

  • $ 2 000
  • Company report
  • April 2016
  • by Global Markets Direct

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016’, provides an overview of the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.